Avalyn is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including idiopathic pulmonary fibrosis and other interstitial lung diseases. Our lead candidate, AP01, is a Phase 2b-ready inhaled formulation of pirfenidone in development for the treatment of pulmonary fibrosis

Avalyn Pharma Inc.

Celebrating the remarkable achievements of Lyn Baranowski and all #WomenInScience! Your groundbreaking work continues to inspire us all.

Avalyn announced this morning that Lyn Baranowski, Chief Executive Officer, will participate in three upcoming investor conferences.

For more details: https://lnkd.in/g2pe-Nij

Avalyn is excited to welcome Scott Beardsley of Novo Ventures (US) to our Board of Directors. With Scott’s extensive background as an investor and expert in financing, we know his guidance will be instrumental in helping take Avalyn to its next stages of growth. We bid farewell to Peter Moldt, who is stepping off our Board, and we want to recognize and thank him for his contributions to the company. We are deeply grateful to Peter and the entire team at Novo Ventures for their partnership and helping drive our lead inhaled #pulmonaryfibrosis treatment candidates forward into the clinic.

Avalyn CEO Lyn Baranowski is participating in a virtual panel discussion later today hosted by Boost by BioBreak. Join us for a lively discussion on biotech fundraising led by Stephanie Oestreich, Managing Director of Myeloma Investment Fund, and featuring fellow biotech leaders Lital Gilad-Shaoulian of PurposeBio and Catherine Sabatos-Peyton of Larkspur Biosciences.

Register here: https://lnkd.in/gm3afDZU

#leadership #womenleaders #femaleleadership #biotech #lifesciences #BoostbyBioBreak

In the early days of Lyn Baranowski’s career, she was struck by how little research and development was going on with lung diseases and how critical these illnesses are. Today, she is the CEO of Avalyn Pharma Inc. and brings more than two decades of experience leading a vast array of functions in biotech, big pharma, and venture capital firms with a focus on the respiratory therapeutic area.

Baranowski has a passion for working in smaller companies, building teams and pipelines, and making a difference which is clear to her peers. At the end of September, Avalyn closed an oversubscribed $175 million Series C financing to now support a lot of exciting initiatives in the works.

Learn more in our latest #BehindTheBreakthrough spotlight – link in comments. 

#biotech #healthcare #startupstories
Ketan Patel

Avalyn announced this morning that Lyn Baranowski, Chief Executive Officer, will provide a corporate overview presentation and participate in a fireside chat at the upcoming 2023 RBC Capital Markets Healthcare Private Company Conference. Management will also participate in one-on-one meetings with investors at the conference. For more details: https://lnkd.in/gVXpnV6w

Avalyn is committed to advancing the treatment of #pulmonaryfibrosis (PF) for patients across the globe, and supporting the professional development of the #researchers working to develop innovative treatments for PF is integral to this goal.

We are proud to sponsor the Centre of Research Excellence in Pulmonary Fibrosis and the CREATE Professional Development Weekend, which aims to equip the next generation of researchers with the training and skills to lead PF research.

We are excited to engage with the #PF community at the Pulmonary Fibrosis Foundation PFF Summit 2023, where we will present data from our AP01 and AP02 inhaled therapeutics programs. Three posters will be presented today from 5:00 – 8:00 p.m. ET, and you can find us at booth #204 throughout the Summit.

For more details: https://lnkd.in/gmqrmg3m

We couldn’t be happier to announce the newest members of the Avalyn team! Join us in welcoming the following accomplished individuals to Avalyn.
 
Craig Conoscenti,MD,FCCP,ATSF: Senior Vice President, Clinical Development
Jim Bishop: Senior Vice President, Business Operations
Allison Trucillo, MD: Vice President, Medical Affairs
Rebecca Boone: Vice President, Clinical Operations

Read our press release here: https://lnkd.in/efnVpAVt

We’re incredibly proud of the dedication to the #pulmonaryfibrosis patient community that our employees demonstrate both inside Avalyn and in their personal lives.
 
Today, we’re highlighting Samiran De, who participated in the Pulmonary Fibrosis Foundation (PFF) National Walk Day in memory of his uncle, a #PF patient who passed away after a year-and-a-half battle with the disease. The Samiran De Team achieved its fundraising goal to help support the PF community.

Spirovant is a biopharmaceutical company focused on developing gene therapies for the treatment of severe respiratory diseases.

Spirovant

Savara is a pharmaceutical company dedicated to developing novel therapies for the treatment of rare respiratory diseases.

Savara

Lung Therapeutics is a biopharmaceutical company specializing in developing treatments for severe lung diseases, including fibrosis and other respiratory conditions.

Lung Therapeutics

Novoclinica Inc is a biopharmaceutical company engaged in the development of therapies for various respiratory diseases and related conditions.

Novoclinica Inc

Pulmokine Inc is a pharmaceutical company focused on developing innovative treatments for respiratory diseases, including pulmonary fibrosis and related conditions.

Pulmokine Inc

UCB is a global biopharmaceutical company that develops and markets therapies for various medical conditions, including respiratory diseases.

Genentech is a leading biotechnology company known for its innovative treatments for a wide range of diseases, including respiratory conditions.

Genentech

Cipla is a global pharmaceutical company that develops and markets a wide range of medications, including treatments for respiratory diseases.

Cipla

Biogen is a leading biotechnology company that focuses on developing therapies for neurological and respiratory conditions.

Biogen

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including Idiopathic Pulmonary Fibrosis (IPF) and other Interstitial Lung Diseases (ILD).

Associate Director Human Resources

Board Member

HUMAN RESOURCES MANAGER

CASA / VGAL Volunteer

Web Marketing Team Member - VOLUNTEER

OFFICE / HUMAN RESOURCES MANAGER

People and Culture Leader

Alyssa Black

Consultant

President

Sr. Director Product Development

Mark Surber

Associate Director, Clinical Data Management

Supervisor- Clinical data management, Immunotherapy

Senior Data Analyst

Senior Data Consultant

Scientific Programmer

Graduate Research Assistant - School of Biomedical Informatics

Clinical Data Management Leader / Project Management/ Collaborator/ Data driven

Deepthi Nair

Chief Financial Officer / Chief Business Officer

Chief Operating and Financial Officer

Chief Financial Officer

Vice President, Commercial Operations, Corporate Strategy & Business Development

Vice President, Corporate and Business Development

Senior Director, Business Development

Douglas Carlson

Chief Medical Officer

Medical Expert/Executive Director, IPF/ILD

Director, Medical Affairs, PAH & IPF

Chief Medical Officer | Advanced Lung Diseases

Howard Lazarus

Director, Field Based Medicine

Senior Associate Director, Regional Integration Lead

Associate Director, Medical Science Liaison

Medical Liaison Growth Hormone Disorders

Research Fellow

Post-doc Fellow

Graduate Student Researcher

Passionate Advocate of Field-Based Medical Affairs & Clinical Trials | Expert in Insight Management | Champion of Continuous Improvement & Project Management | Lean Six Sigma & Product Owner Certified

Nicole Krupp

Senior Medical Director

Consultant Respiratory Physician (equiv Attending Pulmonologist), Interstitial Lung Disease (ILD)

Felix Woodhead

Associate Director, Corporate Development

Senior Analyst, Franchise Research & Analytics - AbbVie Patient Services

Senior Analyst, Marketing Insights & Analytics – Patient Services

Consultant at PRECISIONadvisors (formerly Precision Xtract)

Analyst at Precision Xtract (formerly Insight Strategy Advisors)

Analyst

Intern

Corporate Development Manager

Michael Jaharis

Chief Operating Officer

President & CDO, Metabolic Diseases & Neurology

President, Research & Development

Chief Development Officer

SVP, Nonclinical Research

VP, Nonclinical Research

Director, Safety Assessment Projects

Senior Manager, Safety Assessment Project Development

Toxicologist/Manager, Safety Assessment Projects

Manager, Safety Assessment & DMPK

Toxicologist

Biotech Executive | R&D | Operations

Melissa Rhodes

Senior Director, Pharmacology and Toxicology

Director, Preclinical Development

Senior Director

Senior Director, Pharmacology and Toxicology at Avalyn Pharma

Steven Dvm

Director Of Product Development

Manager (Inhalation)

Sr Manager (R&D)

Project Manager

Past Chair

Pharmaceutical Product Development Expert

Samiran De

Member of the Board of Directors

Senior Vice President, Corporate Development & Strategy

Vice President, Commercial Development

Director

Senior Policy Advisor

International Trade Analyst

CEO at Avalyn Pharma

Lyn Baranowski

Senior Associate

Associate

Senior Consultant

New Biology Ventures Fellow

Graduate Research Assistant

Associate Director, Corporate Development at Avalyn Pharma

Mai Tanaka-Wakefield

Drug Development |Translational Science Senior Director of Nonclinical Development and Translational Science

Director Nonclinical Development

Associate Director of Translational Medicine

Manager, Translational Medicine

Postdoctoral Fellow- Nonclinical Drug Development

ORISE Postdoctoral Fellow

Undergraduate

Drug Development |Translational Science
Senior Director of Nonclinical Development and Translational Science at Avalyn Pharma

news impact assignment basic	general	May 4, 2024 5:57 AM	fb1269de
public peers	general	May 4, 2024 5:57 AM	400697c3
news daily refresh	general	Jul 25, 2024 12:00 PM	9466bfdb
news processing daily refresh	general	May 21, 2024 2:47 AM	956159ae
news impact assignment daily	general
news processing basic	general	May 4, 2024 5:57 AM	f96da5bc
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 4, 2024 5:57 AM	c4983de6
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 4, 2024 5:57 AM	57e80e8d
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:AVALYNPHARMA

Avalyn Pharma